Europe's industry wants urgent action over "detrimental" effects of price referencing
This article was originally published in SRA
Executive Summary
The European pharmaceutical industry body, EFPIA, says there is an "urgent need for action" to deal with the "detrimental" problem of international reference pricing, a tool that is used by the bulk of EU countries (24 out of 27) and has a downward effect on drug prices.